Vincerx Pharma (VINC) Proxy Filing summary

Executive summary

• Amendment #2 to the binding term sheet for a business combination increases the minimum value to be received by one party's stockholders from $13.66 million to $14.16 million, effective January 31, 2025.

• The requirement for the other party to provide the remaining $500,000 in interim financing is irrevocably waived.

• The equity holders of one party will own 95% and the other 5% of the combined company, subject to the minimum value adjustment.

• Forward-looking statements highlight risks related to due diligence, negotiation of a definitive merger agreement, capital requirements, and market acceptance.

Voting matters and shareholder proposals

• A proxy statement will be filed with the SEC regarding the proposed merger, and stockholders will be asked to approve the transaction.

• Directors and officers of both companies may be considered participants in the proxy solicitation.

Board of directors and corporate governance

• Information about directors, executive officers, and their compensation is available in prior proxy statements and SEC filings.

• Updated information on security ownership and potential participants will be provided in future SEC filings.